产品说明书
Tauroursodeoxycholate sodium
 |
同义名 : | 牛磺熊脱氧胆酸钠 ;Tauroursodeoxycholic acid sodium;UR 906 sodium;Ursodeoxycholyltaurine sodium;TUDC;Sodium Tauroursodeoxycholate;TUDCA sodium |
| CAS号 : | 35807-85-3 | |
| 货号 : | A154752 | |
| 分子式 : | C26H45NNaO6S | |
| 纯度 : | 99%+ | |
| 分子量 : | 522.693 | |
| MDL号 : | - | |
| 存储条件： |
粉末 Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(200.88 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO H2O: 100 mg/mL(191.32 mM)，配合低频超声助溶 |
|
| 动物实验配方： |
PO 0.5% CMC-Na 35 mg/mL clear |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Tauroursodeoxycholate Sodium is a water-soluble bile acid used in the treatment of gallstones and cirrhosis. Tauroursodeoxycholate (TUDC) is well known to protect against glycochenodeoxycholate (GCDC)-induced apoptosis in rat hepatocytes. While GCDC upregulated the expression of several pro-inflammatory genes, co-perfusion with TUDC increased the expression of pro-proliferative and anti-apoptotic p53 target genes[3]. After the induction of colitis for 24h, the mice were administrated orally with tauroursodeoxycholate (20, 40 and 60mg/kg) and sulfasalazine (500mg/kg) by gavage for 7 consecutive days. Treatment with different doses of tauroursodeoxycholate (20, 40 and 60mg/kg) significantly improved the body weight change, decreased the macroscopic and histopathological scores. Compared with the model group, the accumulation of MPO (myeloperoxidase) activity, the colonic tissue levels of IL-1β, IFN-γ and TNF-α were significantly reduced in the tauroursodeoxycholate treated groups. Moreover, tauroursodeoxycholate assuaged the symptoms of colitis[4]. Tauroursodeoxycholate (360 μ mol / kg, i.v.) significantly inhibited the decrease of bile flow and increased the activities of serum alkaline phosphatase, leucine aminopeptidase and alanine aminotransferase, as well as the concentrations of cholesterol, phospholipids and bile acids in rats with bile obstruction induced by phalloidin[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03127514 | Amyotrophic Lateral Sclerosis ... 展开 >> Motor Neuron Disease Neuromuscular Diseases Neurodegenerative Diseases Spinal Cord Diseases TDP-43 Proteinopathies Nervous System Diseases Central Nervous System Diseases 收起 << | Phase 2 | Recruiting | May 2019 | - |
| NCT00771901 | - | Completed | - | - | |
| NCT03533257 | Alzheimer Disease | Phase 2 | Recruiting | September 1, 2020 | United States, Illinois ... 展开 >> Rush University Medical Center Recruiting Chicago, Illinois, United States, 60612 Contact: Judy Phillips 312-942-0050 Judy_Phillips@rush.edu United States, Kansas University of Kansas Clinical Research Center Recruiting Fairway, Kansas, United States, 66205 Contact: KUMC Recruitment Division 913-588-0555 KUAMP@kumc.edu United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Alison J McManus, DNP 617-643-4848 ajmcmanus@mgh.harvard.edu Contact: John Ernandez 617-643-4047 jernandez@partners.org United States, New Jersey Rowan University Not yet recruiting Stratford, New Jersey, United States, 08084 Contact: Lauren Fedor 856-566-6003 fedor@rowan.edu United States, New York Mount Sinai Alzheimer's Disease Research Center Not yet recruiting New York, New York, United States, 10029 Contact: Caroline Meuser 212-659-8885 caroline.meuser@mssm.edu Columbia University Recruiting New York, New York, United States, 10032 Contact: Ruth Tejeda 212-305-7661 rbt41@cumc.columbia.edu United States, Pennsylvania Penn Memory Center Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Laura Schankel 215-349-8727 laura.schankel@pennmedicine.upenn.edu 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.91mL 0.38mL 0.19mL |
9.57mL 1.91mL 0.96mL |
19.13mL 3.83mL 1.91mL |
| 参考文献 |
|---|